http://www.nebraskaoncology.org/daily1.0 http://www.nebraskaoncology.org/nebraska-oncology-society2020-07-06T17:32Znever1.0 http://www.nebraskaoncology.org/membership/corporate-membership2025-10-21T16:06Zyearly http://www.nebraskaoncology.org/crizotinib-vs-placebo-patients-tumors-harboring-alk-fusion-protein-e45122019-03-08T16:37Znever http://www.nebraskaoncology.org/randomized-trial-erlotinib-vs-placebo-patients-completely-resected-egfr-mutant-nonsmall-cell-lung2019-03-08T16:38Znever http://www.nebraskaoncology.org/adjuvant-lung-cancer-enrichment-marker-identification-and-sequencing-trial-a1512162019-03-08T16:35Znever http://www.nebraskaoncology.org/randomized-trial-dabrafenib-trametinib-followed-ipilimumab-nivolumab-progression-vs-ipilimumab2019-03-08T16:11Znever http://www.nebraskaoncology.org/randomized-placebo-controlled-trial-aspirin-adjuvant-therapy-node-positive-her2-neg-breast-cancer2019-03-08T16:23Znever http://www.nebraskaoncology.org/contact2020-01-20T21:27Znever http://www.nebraskaoncology.org/randomized-trial-evaluating-role-weight-loss-adjuvant-treatment-overweight-and-obese-women-early2019-03-08T18:26Znever http://www.nebraskaoncology.org/about/new-drugs-therapies2025-05-14T16:59Zyearly http://www.nebraskaoncology.org/randomized-study-assess-efficacy-and-safety-combination-ublituximab-tgr-1202-or-without-bendamustine2019-03-08T21:29Znever http://www.nebraskaoncology.org/randomized-study-evaluating-efficacy-and-safety-canakinumab-vs-placebo-adjuvant-therapy-subjects2019-03-12T16:19Znever http://www.nebraskaoncology.org/study-evaluate-safety-and-efficacy-cd40-agonistic-antibody-apx005m-administered-combination2020-04-13T17:22Znever http://www.nebraskaoncology.org/pivotal-randomized-open-label-study-tumor-treating-fields-ttfields-combination-pd-1-inhibitors-or2019-03-08T16:37Znever http://www.nebraskaoncology.org/study-ipilimumab-and-nivolumab-adjuvant-therapy-resected-mucosal-melanoma-mel-16-252-salvo2019-03-08T16:12Znever http://www.nebraskaoncology.org/myelodysplastic-syndrome-mds-and-acute-myeloid-leukemia-aml-disease-registry-connect2019-03-08T21:17Znever http://www.nebraskaoncology.org/multicenter-randomized-double-blind-placebo-controlled-study-ibrutinib-combination-rituximab-vs2019-03-08T21:23Znever http://www.nebraskaoncology.org/prospective-research-assessment-multiple-myeloma-observational-evaluation-preamble2019-03-08T21:08Znever http://www.nebraskaoncology.org/randomized-trial-evaluate-safety-and-efficacy-endotag-1-plus-gemcitabine-versus-gemcitabine-alone2019-03-08T16:20Znever http://www.nebraskaoncology.org/randomized-open-label-controlled-study-m7824-versus-pembrolizumab-first-line-treatment-patients-pd2019-03-12T17:22Znever http://www.nebraskaoncology.org/study-comparing-venetoclax-fulvestrant-vs-fulvestrant-women-estrogen-receptor-positive-her2-negative2019-03-08T16:23Znever http://www.nebraskaoncology.org/blood-collection-evaluate-biomarkers-subjects-untreated-solid-tumors2019-03-08T20:09Znever http://www.nebraskaoncology.org/protocol-research-database-hematopoietic-cell-transplantation-and-cellular-therapies-cibmtr-research2019-03-08T21:10Znever http://www.nebraskaoncology.org/trial-evaluate-efficacy-and-safety-palbociclib-anti-her2-therapy-endocrine-therapy-vs-anti-her22019-03-08T16:25Znever http://www.nebraskaoncology.org/randomized-trial-olaparib-nsc-747856-administered-concurrently-radiotherapy-versus-radiotherapy2019-03-08T16:25Znever http://www.nebraskaoncology.org/clinical-trial-evaluating-post-mastectomy-chest-wall-and-regional-nodal-xrt-and-post-lumpectomy2019-03-08T16:23Znever http://www.nebraskaoncology.org/integrated-cancer-repository-cancer-research-icare2-–-breast-cancer-collaborative-repository-bccr2019-03-08T16:23Znever http://www.nebraskaoncology.org/trial-evaluate-efficacy-and-safety-mk-3475-pembrolizumab-adjuvant-therapy-triple-receptor-negative2019-03-08T16:25Znever http://www.nebraskaoncology.org/study-mfolfox6/bevacizumab-combination-chemotherapy-or-without-atezolizumab-or-atezolizumab2019-03-08T16:22Znever http://www.nebraskaoncology.org/randomized-trial-standard-chemotherapy-alone-or-combined-atezolizumab-adjuvant-therapy-patients2019-03-08T16:20Znever http://www.nebraskaoncology.org/randomized-study-trastuzumab-and-pertuzumab-tp-compared-cetuximab-and-irinotecan-cetiri-advanced2019-03-08T16:19Znever http://www.nebraskaoncology.org/study-nivolumab-after-combined-modality-therapy-cmt-high-risk-anal-cancer-ea21652019-03-08T16:22Znever http://www.nebraskaoncology.org/study-comparing-tislelizumab-platinum-and-fluoropyrimidine-versus-placebo-plus-platinum-and2019-03-08T16:21Znever http://www.nebraskaoncology.org/pivotal-randomized-open-label-study-tumor-treating-fields-concomitant-gemcitabine-and-nab-paclitaxel2019-03-08T16:20Znever http://www.nebraskaoncology.org/trial-comparing-paclitaxel-ifosfamide-and-cisplatin-high-dose-chemo-using-mobilizing-paclitaxel-plus2019-03-08T16:17Znever http://www.nebraskaoncology.org/study-androgen-annihilation-high-risk-biochemically-relapsed-prostate-cancer-aft-192019-03-08T16:15Znever http://www.nebraskaoncology.org/antiandrogen-therapy-and-radiation-therapy-or-without-docetaxel-treating-patients-prostate-cancer2019-03-08T16:15Znever http://www.nebraskaoncology.org/trial-salvage-radiotherapy-or-without-enhanced-anti-androgen-therapy-apalutamide-recurrent-prostate2019-03-08T16:17Znever http://www.nebraskaoncology.org/trial-standard-systemic-therapy-sst-versus-standard-systemic-therapy-plus-definitive-treatment2019-03-08T16:13Znever http://www.nebraskaoncology.org/study-testing-addition-nivolumab-pre-and-post-nephrectomy-patients-renal-cell-carcinoma-ea81432019-03-08T16:16Znever http://www.nebraskaoncology.org/study-ibrutinib-combination-therapy-selected-advanced-gastrointestinal-and-genitourinary-tumors-pcyc2019-03-08T16:16Znever http://www.nebraskaoncology.org/study-high-dose-interleukin-2-vs-high-dose-interleukin-2-plus-entinostat-untreated-advanced-renal2019-03-08T16:16Znever http://www.nebraskaoncology.org/randomized-double-blind-phase-iii-study-pembrolizumab-vs-placebo-combination-neoadjuvant2019-03-08T16:22Znever http://www.nebraskaoncology.org/phase-ii-study-olaparib-monotherapy-participants-previously-treated-homologousrecombination-repair2019-03-08T19:46Znever http://www.nebraskaoncology.org/phase-i-study-cdx-1140-fully-human-agonist-anti-cd40-monoclonal-antibody-monotherapy-or-combination2019-03-08T18:45Znever http://www.nebraskaoncology.org/randomized-double-blind-study-cabozantinib-vs-placebo-patients-advanced-neuroendocrine-or-carcinoid2019-03-08T19:56Znever http://www.nebraskaoncology.org/treatment-ipilimumab-and-nivolumab-rare-cancers-dart-dual-anti-crla-4-and-anti-pd-1-blockade-rare2019-03-08T20:20Znever http://www.nebraskaoncology.org/randomized-study-nivolumab-ipilimumab-or-ipilimumab-alone-advanced-melanoma-patients-refractory-anti2019-03-08T16:10Znever http://www.nebraskaoncology.org/randomized-study-adjuvant-vs-neoadjuvant-pembrolizumab-clinically-detectable-stage-iii-iv-high-risk2020-04-13T16:48Znever http://www.nebraskaoncology.org/sequential-2-arm-open-label-study-evaluate-teh-effects-encorafenib-combination-binimetinib-patients2019-03-08T16:11Znever http://www.nebraskaoncology.org/about2019-10-10T16:37Znever http://www.nebraskaoncology.org/randomized-double-blind-placebo-controlled-study-abiraterone-acetate-plus-prednisone-or-without2019-03-08T16:14Znever http://www.nebraskaoncology.org/randomized-trial-gemcitabine-cisplatin-and-nab-paclitaxel-vs-gemcitabine-and-cisplatin-newly2019-03-08T16:19Znever http://www.nebraskaoncology.org/randomized-trial-adjuvant-radiation-vs-chemoradiation-intermediate-risk-stage-i/iia-cervical-cancer2019-03-12T16:06Znever http://www.nebraskaoncology.org/randomized-study-concurrent-chemotherapy-and-pelvic-radiation-or-without-adjuvant-chemotherapy-high2019-03-12T16:00Znever http://www.nebraskaoncology.org/randomized-trial-pelvic-radiation-or-without-concurrent-weekly-cisplatin-patients-pelvic-only2019-03-11T20:12Znever http://www.nebraskaoncology.org/randomized-study-combination-cediranib-and-olaparib-compared-cediranib-or-olaparib-alone-or-standard2019-03-11T20:08Znever http://www.nebraskaoncology.org/study-testing-addition-antibody-atezolizumab-chemotherapy-liposomal-doxorubicin-and-bevacizumab2019-03-12T16:03Znever http://www.nebraskaoncology.org/study-pembrolizumab-and-epacadostat-recurrent-clear-cell-carcinoma-ovary-gy0162019-03-11T20:13Znever http://www.nebraskaoncology.org/randomized-trial-paclitaxel-and-carboplatin-vs-bleomycin-etoposide-and-cisplatin-newly-diagnosed2019-03-11T20:09Znever http://www.nebraskaoncology.org/randomized-study-individualized-treatment-nasopharyngeal-carcinoma-based-biomarker-epstein-barr2019-03-08T20:56Znever http://www.nebraskaoncology.org/de-escalation-protocol-hpv-mediated-oropharyngeal-squamous-cell-carcinaoma-based-american-joint2019-03-08T16:28Znever http://www.nebraskaoncology.org/randomized-study-adjuvant-concurrent-radiation-and-chemotherapy-vs-radiation-alone-resected-high2019-03-08T20:53Znever http://www.nebraskaoncology.org/randomized-multidrug-platform-study-durvalumab-alone-or-combination-novel-agents-subjects-locally2019-03-08T16:37Znever http://www.nebraskaoncology.org/master-protocol-evaluate-biomarker-driven-therapies-and-immunotherapies-previously-treated-nonsmall2019-03-12T16:13Znever http://www.nebraskaoncology.org/registry-lung-screening-excellence2019-03-07T18:39Znever http://www.nebraskaoncology.org/observational-study-assessing-clinical-effectiveness-veristrat-test-and-validating-immunotherapy2019-03-08T16:35Znever http://www.nebraskaoncology.org/open-label-study-investigate-efficacy-and-safety-atezolizumab-neoadjuvant-and-adjuvant-therapy2020-04-13T17:25Znever http://www.nebraskaoncology.org/randomized-double-blind-placebo-controlled-pilot-study-oral-selective-peripheral-opioid-receptor2019-03-12T17:19Znever http://www.nebraskaoncology.org/study-osimertinib-advanced-nonsmall-cell-lung-cancer-patients-exon20-mutations-egfr-ea51622019-03-12T17:25Znever http://www.nebraskaoncology.org/randomized-trial-comparing-adjuvant-pembrolizumab-vs-standard-care-observation-completely-resected2019-03-08T19:52Znever http://www.nebraskaoncology.org/annual-midwest-regional-mid-year-review-20202022-10-05T15:26Znever http://www.nebraskaoncology.org/treatment-patterns-outcomes-and-patient-reported-health-related-quality-life-prospective-disease2019-09-25T17:47Znever http://www.nebraskaoncology.org/randomized-phase-ii/iii-study-conventional-chemotherapy-plus-or-minus-uproleselan-older-adults-acute2019-09-25T18:29Znever http://www.nebraskaoncology.org/randomized-study-ibrutinib-plus-obinutuzumab-vs-ibrutinib-plus-venetoclax-and-obinutuzumab-untreated2019-09-25T18:31Znever http://www.nebraskaoncology.org/randomized-study-ruxolitinib-combination-bcr-abl-tyrosine-kinase-inhibitors-chonic-myeloid-leukemia2019-09-25T18:34Znever http://www.nebraskaoncology.org/study-daratumumab/rhuph20-plus-lenalidomide-or-lenalidomide-post-autologous-stem-cell-transplant2019-09-25T18:37Znever http://www.nebraskaoncology.org/randomized-double-blind-trial-paclitaxel/trastuzumab/pertuzumab-atezolizumab-or-placebo-first-line2019-09-25T18:44Znever http://www.nebraskaoncology.org/randomized-post-operative-trial-platinum-based-chemotherapy-vs-capecitabine-patients-residual-triple2019-09-25T19:14Znever http://www.nebraskaoncology.org/study-ipilimumab-cabozantinib-and-nivolumab-rare-genitourinary-tumors-a0317022019-09-25T19:31Znever http://www.nebraskaoncology.org/randomized-trial-concurrent-chemoradiotherapy-or-without-atezolizumab-localized-muscle-invasive2019-09-25T19:32Znever http://www.nebraskaoncology.org/nivolumab-and-ipilimumab-followed-nivolumab-vs-cabozantinib-nivolumab-trial-metastatic-untreated2019-09-25T19:35Znever http://www.nebraskaoncology.org/trial-atezolizumab-plus-chemotherapy-after-progression-single-agent-pd-1-or-pd-l1-inhibitor2019-09-25T19:38Znever http://www.nebraskaoncology.org/randomized-study-first-line-immunotherapy-alone-or-combination-chemotherapy-induction/maintenance-or2019-09-25T20:29Znever http://www.nebraskaoncology.org/study-sitravatinib-combination-nivolumab-vs-docetaxel-patients-advanced-nonsquamous-nonsmall-cell2019-09-25T20:38Znever http://www.nebraskaoncology.org/biomarker-driven-protocol-previously-treated-alk-positive-nonsquamous-nonsmall-cell-lung-cancer2019-09-25T20:40Znever http://www.nebraskaoncology.org/trial-neoadjuvant-amg-232-concurrent-preoperative-radiotherapy-wild-type-p53-soft-tissue-sarcoma2019-10-02T19:22Znever http://www.nebraskaoncology.org/randomized-open-label-trial-vigil-combination-irinotecan-and-temozolomide-second-line-regimena-ewing2019-09-25T20:55Znever http://www.nebraskaoncology.org/randomized-trial-avelumab-plus-cetuximab-vs-avelumab-alone-advanced-cutaneous-squamous-cell2019-09-25T20:59Znever http://www.nebraskaoncology.org/randomized-placebo-controlled-double-blind-study-adjuvant-cemiplimab-vs-placebo-after-surgery-and2019-10-01T17:44Znever http://www.nebraskaoncology.org/study-cabozantinib-compared-placebo-subjects-radioiodine-refractory-differentiated-thyroid-cancer2019-10-01T17:46Znever http://www.nebraskaoncology.org/study-asp1948-targeting-immune-modulatory-receptor-subjects-advanced-solid-tumors-1948-cl-01012019-10-01T19:24Znever http://www.nebraskaoncology.org/dose-escalation-study-cabozantinib-administered-alone-or-combination-atezolizumab-subjects-locally2019-10-01T19:29Znever http://www.nebraskaoncology.org/treatment-resistance-following-anticancer-therapies-181502019-10-01T19:30Znever http://www.nebraskaoncology.org/basket-study-oral-selective-pan-fgfr-inhibitor-debio-1347-subjects-solid-tumors-harboring-fusion2019-10-01T19:32Znever http://www.nebraskaoncology.org/first-human-open-label-dose-escalation-trial-expansion-cohorts-evaluate-safety-gen1029-patents2019-10-01T19:39Znever http://www.nebraskaoncology.org/study-evaluate-ribociclib-combination-nonsteroidal-aromatase-inhibitor-treatment-women-advanced2019-10-01T20:01Znever http://www.nebraskaoncology.org/randomized-double-blind-trial-tucatinib-or-placebo-combination-ado-trastuzumab-emtansine-t-dm12019-10-01T20:04Znever http://www.nebraskaoncology.org/study-regorafenib-and-anti-pd-1-patients-microsatellite-stable-colorectal-cancer-190962019-10-01T20:09Znever http://www.nebraskaoncology.org/study-neoadjuvant-chemotherapy-alone-vs-neoadjuvant-chemotherapy-plus-nivolumab-or2019-10-02T16:28Znever http://www.nebraskaoncology.org/study-immu-132-metastatic-urothelial-cancer-after-failure-platinum-based-regimen-or-anti-pd-1/pd-l-12019-10-02T16:34Znever http://www.nebraskaoncology.org/study-nktr-262-combination-nktr-214-and-nktr-214-plus-nivolumab-patients-locally-advanced-or2019-10-02T16:58Znever http://www.nebraskaoncology.org/double-blind-trial-pembrolizumab-plus-enzalutamide-vs-placebo-plus-enzalutamide-patients-metastatic2019-10-02T16:44Znever http://www.nebraskaoncology.org/study-pembrolizumab-olaparib-vs-abiraterone-or-enzalutamide-patients-metastatic-castration-resistant2019-10-02T16:49Znever http://www.nebraskaoncology.org/double-blind-study-pembrolizumabdocetaxelprednisone-vs-placebodocetaxelprednisone-patients2019-10-02T16:53Znever http://www.nebraskaoncology.org/study-regn5678-cemiplimab-patients-metastatic-castration-resistant-prostate-cancer-r5678-onc-18792019-10-02T16:54Znever http://www.nebraskaoncology.org/open-label-study-assess-safety-and-tolerability-and-pharmacokinetics-capivasertib-combination-novel2019-10-02T17:00Znever http://www.nebraskaoncology.org/randomized-double-blind-study-cabozantinib-combinaiton-nivolumab-and-ipilimumab-vs-nivolumab-and2019-10-02T17:04Znever http://www.nebraskaoncology.org/pharmacokinetics-pharmacodynamics-safety-and-tolerability-multiple-dose-regimens-mt-3724-gemzar-and2019-10-02T17:10Znever http://www.nebraskaoncology.org/randomized-study-comparing-two-intermittent-dosing-schedules-duvelisib-subjects-indolent-nonhodgkins2019-10-02T17:29Znever http://www.nebraskaoncology.org/randomized-double-blind-placebo-controlled-study-evaluating-teh-efficacy-and-safety-copanlisib2019-10-02T17:42Znever http://www.nebraskaoncology.org/study-safety-pharmacodynamics-and-efficacy-mt-3724-treatment-relapsed-or-refractory-diffuse-large-b2019-10-02T17:51Znever http://www.nebraskaoncology.org/open-label-study-assess-anti-tumor-activity-and-safety-regn1979-anti-cd20-x-anti-cd3-bispecific2019-10-02T17:55Znever http://www.nebraskaoncology.org/randomized-double-blind-study-adjuvant-immunotherapy-nivolumab-vs-placebo-after-complete-resection2020-04-13T16:48Znever http://www.nebraskaoncology.org/study-imo-2125-combination-ipilimumab-vs-ipilimumab-alone-subjects-anti-pd-1-refractory-melanoma2019-10-02T19:10Znever http://www.nebraskaoncology.org/open-label-study-intratumoral-tavo-plus-electroporation-combination-pembrolizumab-patients-stage-iii2019-10-02T19:14Znever http://www.nebraskaoncology.org/clinical-trials2019-03-06T19:13Znever http://www.nebraskaoncology.org/san-antonio-breast-cancer-symposium-review-02020-12-16T21:27Znever http://www.nebraskaoncology.org/2020-san-antonio-breast-cancer-symposium-review2020-11-19T21:00Znever http://www.nebraskaoncology.org/study-2-ribociclib-doses-combination-aromatase-inhibitors-women-hr-her2-advanced-breast-cancer-pmr2020-04-13T17:50Znever http://www.nebraskaoncology.org/window-study-sar439859-versus-letrozole-er-her2-pre-operative-post-menopausal-primary-breast-cancer2020-04-13T17:51Znever http://www.nebraskaoncology.org/study-adagloxad-simolenin-obi-822-and-obi-821-versus-placebo-treatment-high-risk-early-stage-triple2020-04-13T17:53Znever http://www.nebraskaoncology.org/acalabrutinib-safety-study-untreated-and-relapsed-or-refractory-chronic-lymphocytic-leukemia2020-04-13T17:54Znever http://www.nebraskaoncology.org/trial-assess-efficacy-and-safety-lenvatinib-combination-pembrolizumab-participants-advanced-melanoma2020-04-13T17:57Znever http://www.nebraskaoncology.org/phase-i-study-cdx-1140-fully-human-agonist-anti-cd40-monoclonal-antibody-monotherapy-or-02020-04-13T18:04Znever http://www.nebraskaoncology.org/phase-i-study-cdx-1140-fully-human-agonist-anti-cd40-monoclonal-antibody-monotherapy-or-12020-04-13T18:04Znever http://www.nebraskaoncology.org/phase-i-study-cdx-1140-fully-human-agonist-anti-cd40-monoclonal-antibody-monotherapy-or-22020-04-13T18:05Znever http://www.nebraskaoncology.org/study-asp1948-targeting-immune-modulatory-receptor-subjects-advanced-solid-tumors-1948-cl-0101-02020-04-13T18:08Znever http://www.nebraskaoncology.org/study-asp1948-targeting-immune-modulatory-receptor-subjects-advanced-solid-tumors-1948-cl-0101-12020-04-13T18:09Znever http://www.nebraskaoncology.org/study-asp1948-targeting-immune-modulatory-receptor-subjects-advanced-solid-tumors-1948-cl-0101-22020-04-13T18:10Znever http://www.nebraskaoncology.org/study-asp1948-targeting-immune-modulatory-receptor-subjects-advanced-solid-tumors-1948-cl-0101-32020-04-13T18:10Znever http://www.nebraskaoncology.org/study-asp1948-targeting-immune-modulatory-receptor-subjects-advanced-solid-tumors-1948-cl-0101-42020-04-13T18:10Znever http://www.nebraskaoncology.org/study-asp1948-targeting-immune-modulatory-receptor-subjects-advanced-solid-tumors-1948-cl-0101-52020-04-13T18:11Znever http://www.nebraskaoncology.org/open-label-study-asp9801-oncolytic-virus-administered-intratumoral-injection-patients-advanced-02020-04-13T18:13Znever http://www.nebraskaoncology.org/study-evaluate-efficacy-and-safety-pemigatinib-participants-previously-treated-locally-advanced2020-04-13T18:16Znever http://www.nebraskaoncology.org/study-highly-selective-ret-inhibitor-blu667-patients-thyroid-cancer-non-small-cell-lung-cancer-nsclc2020-04-13T18:17Znever http://www.nebraskaoncology.org/study-pf06821497-treatment-adult-patients-relapsed/refractory-small-cell-lung-cancer-castration2020-04-13T18:21Znever http://www.nebraskaoncology.org/study-pf06821497-treatment-adult-patients-relapsed/refractory-small-cell-lung-cancer-castration-02020-04-13T18:22Znever http://www.nebraskaoncology.org/study-pf06821497-treatment-adult-patients-relapsed/refractory-small-cell-lung-cancer-castration-12020-04-13T18:22Znever http://www.nebraskaoncology.org/study-mga271-combination-pembrolizumab-and-combination-mga012-patients-melanoma-squamous-cell-cancer2020-04-13T18:25Znever http://www.nebraskaoncology.org/study-mga271-combination-pembrolizumab-and-combination-mga012-patients-melanoma-squamous-cell-02020-04-13T18:26Znever http://www.nebraskaoncology.org/study-mga271-combination-pembrolizumab-and-combination-mga012-patients-melanoma-squamous-cell-12020-04-13T18:26Znever http://www.nebraskaoncology.org/study-mga271-combination-pembrolizumab-and-combination-mga012-patients-melanoma-squamous-cell-22020-04-13T18:27Znever http://www.nebraskaoncology.org/study-evaluate-enfortumab-vedotin-subjects-previously-treated-locally-advanced-or-metastatic2020-04-13T18:29Znever http://www.nebraskaoncology.org/study-evaluate-enfortumab-vedotin-subjects-previously-treated-locally-advanced-or-metastatic-02020-04-13T18:32Znever http://www.nebraskaoncology.org/study-evaluate-enfortumab-vedotin-subjects-previously-treated-locally-advanced-or-metastatic-12020-04-13T18:32Znever http://www.nebraskaoncology.org/study-evaluate-enfortumab-vedotin-subjects-previously-treated-locally-advanced-or-metastatic-22020-04-13T18:33Znever http://www.nebraskaoncology.org/study-evaluate-enfortumab-vedotin-subjects-previously-treated-locally-advanced-or-metastatic-32020-04-13T18:33Znever http://www.nebraskaoncology.org/study-evaluate-safety-and-activity-ttx030-anti-cd39-combination-budigalimab-and/or-chemotherapy2020-04-13T18:36Znever http://www.nebraskaoncology.org/study-evaluate-safety-and-activity-ttx030-anti-cd39-combination-budigalimab-and/or-chemotherapy-02020-04-13T18:36Znever http://www.nebraskaoncology.org/study-evaluate-safety-and-activity-ttx030-anti-cd39-combination-budigalimab-and/or-chemotherapy-12020-04-13T18:37Znever http://www.nebraskaoncology.org/study-evaluate-safety-and-activity-ttx030-anti-cd39-combination-budigalimab-and/or-chemotherapy-22020-04-13T18:38Znever http://www.nebraskaoncology.org/study-abemaciclib-and-cdk-4/6-inhibitor-combination-fulvestrant-compared-chemotherapy-women-hr2020-04-13T18:41Znever http://www.nebraskaoncology.org/treatment-protocol-tucatinib-combination-capecitabine-and-trustuzumab-patients-previously-treated2020-04-13T18:48Znever http://www.nebraskaoncology.org/study-oral-infigratinib-versus-gemcitabine-cisplatin-subjects-advanced/metastatic-or-inoperable2020-04-13T19:18Znever http://www.nebraskaoncology.org/study-irinotecan-liposome-injection-oxaliplatin-5-fluorouracil/leucovorin-versus-nab-paclitaxel-plus2020-04-13T19:20Znever http://www.nebraskaoncology.org/study-xermelo®-telotristat-ethyl-plus-first-line-chemotherapy-patients-locally-advanced-unresectable2020-04-13T19:21Znever http://www.nebraskaoncology.org/study-relacorilant-combination-nabpaclitaxel-patients-metastatic-pancreatic-ductal-adenocarcinoma2020-04-13T19:23Znever http://www.nebraskaoncology.org/study-cabozantinib-xl184-administered-alone-or-combination-atezolizumab-subjects-locally-advanced-or2020-04-13T19:32Znever http://www.nebraskaoncology.org/study-cabozantinib-xl184-administered-alone-or-combination-atezolizumab-subjects-locally-advanced-02020-04-13T19:33Znever http://www.nebraskaoncology.org/study-cabozantinib-xl184-administered-alone-or-combination-atezolizumab-subjects-locally-advanced-12020-04-13T19:33Znever http://www.nebraskaoncology.org/study-erdafitinib-compared-vinfluine-or-docetaxel-or-pembrolizumab-subjects-advanced-urothelial2020-04-13T19:35Znever http://www.nebraskaoncology.org/study-rucaparib-versus-physicians-choice-therapy-patients-metastatic-castration-resistant-prostate2020-04-13T19:38Znever http://www.nebraskaoncology.org/study-saftey-ttx-030-single-agent-and-combination-pembrolizumab-or-chemotherapy-patients-lymphoma-or2020-04-13T19:42Znever http://www.nebraskaoncology.org/study-saftey-ttx-030-single-agent-and-combination-pembrolizumab-or-chemotherapy-patients-lymphoma-02020-04-13T19:43Znever http://www.nebraskaoncology.org/study-evaluate-subcutaneous-daratumumab-combination-stafnard-mutliple-myeloma-treatment-regimens2020-04-13T19:46Znever http://www.nebraskaoncology.org/trial-evaluating-safety-pharmacokinetics-pharmacodynamics-and-clinical-activity-orally-administered2020-04-13T19:48Znever http://www.nebraskaoncology.org/study-evaluating-safety-and-efficacy-polatuzumab-vedotin-combination-rituximab-plus-gemcitabine-plus2020-04-13T19:50Znever http://www.nebraskaoncology.org/study-evaluate-efficacy-and-safety-single-agent-belantamab-mafodotin-compared-pomalidomide-plus-low2020-04-13T19:51Znever http://www.nebraskaoncology.org/expanded-access-program-belantamab-mafodotin-patients-relapsed/refractory-multiple-myeloma-who-are2020-04-13T19:53Znever http://www.nebraskaoncology.org/umbrella-study-rolling-arms-investigational-agents-either-pembrolizumab-combination-chemotherapy-or2020-04-13T19:55Znever http://www.nebraskaoncology.org/study-brigatinib-alunbrig™-versus-alectinib-alecensa®-advanced-anaplastic-lymphoma-kinase-positive2020-04-13T19:57Znever http://www.nebraskaoncology.org/study-pemetrexed-platinum-chemotherapy-or-without-pembrolizumab-mk3475-tki-resistant-egfr-mutated2020-04-13T19:58Znever http://www.nebraskaoncology.org/study-rrx001-administered-sequentially-platinum-doublet-or-platinum-doublet-third-line-or-beyond2020-04-13T19:59Znever http://www.nebraskaoncology.org/study-investigating-efficacy-and-safety-uv1-vaccination-combination-nivolumab-and-ipilimumab-first2020-04-13T20:01Znever http://www.nebraskaoncology.org/development-and-validation-multiplex-qpcr-short-fragment-cell-free-dna-assay-potential-biomarker2020-04-13T20:04Znever http://www.nebraskaoncology.org/biomarker-study-determine-frequency-dna-repair-defects-men-metastatic-prostate-cancer-191442020-04-13T20:05Znever http://www.nebraskaoncology.org/bespoke-study-ctdna-guided-therapy-colorectal-cancer2020-04-13T20:06Znever http://www.nebraskaoncology.org/study-venetoclax-abt199-plus-chemoimmunotherapy-myc/bcl2-double-hit-and-double-expressing-lymphomas2020-04-13T20:09Znever http://www.nebraskaoncology.org/study-physical-activity’s-relationship-cancer-and-cognition-sparcc2020-04-13T20:10Znever http://www.nebraskaoncology.org/study-de-intensified-chemoradiation-early-stage-anal-squamous-cell-carcinoma-ea21822020-04-13T20:12Znever http://www.nebraskaoncology.org/study-circulating-tumor-dna-predictive-biomarker-adjuvant-chemotherapy-patients-stage-iia-colon2020-04-13T20:14Znever http://www.nebraskaoncology.org/trial-vitamin-d3-supplementation-patients-previously-untreated-metastatic-colorectal-cancer-a0217032020-04-13T20:15Znever http://www.nebraskaoncology.org/study-pevonedistat-combination-carboplatin-and-paclitaxel-advanced-intrahepatic-cholangiocarcinoma2020-04-13T20:16Znever http://www.nebraskaoncology.org/study-pembrolizumab-mk-3475-nsc-776864-addition-paclitaxel-and-carboplatin-measurable-stage-iii-or2020-04-13T20:19Znever http://www.nebraskaoncology.org/clinical-validation-intervenn-ovarian-cancer-liquid-biopsy-vocal-study-ovaca-0012020-04-13T20:20Znever http://www.nebraskaoncology.org/study-tumor-treating-fields-ttfields-200khz-concomitant-weekly-paclitaxel-treatment-recurrent2020-04-13T20:22Znever http://www.nebraskaoncology.org/study-chemotherapy-or-without-pembrolizumab-followed-maintenance-olaparib-or-placebo-first-line2020-04-13T20:23Znever http://www.nebraskaoncology.org/trial-paclitaxel/carboplatin/maintenance-letrozole-versus-letrozole-monotherapy-patients-stage-ii-iv2020-04-13T20:24Znever http://www.nebraskaoncology.org/study-determine-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-combinations-abbv-3682020-04-14T17:20Znever http://www.nebraskaoncology.org/study-rucaparib-patients-genomic-loh-high-and/or-deleterious-brca1/2-mutation-stage-iv-or-recurrent2020-04-13T20:29Znever http://www.nebraskaoncology.org/international-study-durvalumab-following-stereotactic-body-radiation-therapy-sbrt-treatment-patients2020-04-13T20:31Znever http://www.nebraskaoncology.org/mri-brain-surveillance-alone-versus-mri-surveillance-and-prophylactic-cranial-irradiation-pci-trial2020-04-13T20:33Znever http://www.nebraskaoncology.org/limited-stage-small-cell-lung-cancer-ls-sclc-study-chemoradiation-versus-chemoradiation-plus2020-04-13T20:34Znever http://www.nebraskaoncology.org/study-nivolumab-plus-ipilimumab-plus-sargramostim-versus-nivolumab-plus-ipilimumab-patients2020-04-14T17:30Znever http://www.nebraskaoncology.org/study-neoadjuvant-cemiplimab-stage-ii-iv-m0-cutaneous-squamous-cell-carcinoma-r2810-onc-19012020-04-13T20:38Znever http://www.nebraskaoncology.org/study-mga271-combination-pembrolizumab-and-combination-mga012-patients-melanoma-squamous-cell-32020-04-13T20:42Znever http://www.nebraskaoncology.org/study-pembrolizumab-or-without-lenvatinib-evaluate-safety-and-efficacy-pembrolizumab-and-lenvatinib2020-04-13T20:50Znever http://www.nebraskaoncology.org/study-venetoclax-abt199-plus-chemoimmunotherapy-myc/bcl2-double-hit-and-double-expressing-02020-04-14T17:25Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-02020-06-19T19:08Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-12020-06-20T21:30Znever http://www.nebraskaoncology.org/membership2019-10-10T18:41Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-22020-06-15T17:27Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-32020-06-15T17:26Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-42020-07-02T22:05Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-52020-07-01T17:07Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-62020-06-24T19:51Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-72020-06-25T05:43Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-82020-06-24T16:46Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-92020-11-19T21:13Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-102020-06-15T17:26Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-112020-06-19T17:04Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-122020-06-16T23:58Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-132020-06-19T17:42Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-142020-06-19T19:07Znever http://www.nebraskaoncology.org/annual-midwest-regional-asco-review-2020-152020-06-20T21:44Znever http://www.nebraskaoncology.org/events-annual-winter-breast-cancer-symposium2025-11-15T15:20Zyearly http://www.nebraskaoncology.org/11th-annual-midwest-regional-san-antonio-breast-cancer-symposium-review2021-12-02T21:19Znever http://www.nebraskaoncology.org/events-annual-midwest-regional-mid-year-review2025-09-29T17:57Zyearly http://www.nebraskaoncology.org/events-speaker-series2025-08-26T19:44Zyearly http://www.nebraskaoncology.org/evening-speaker-series-virtual-lung-cancer-update2021-03-16T22:08Znever http://www.nebraskaoncology.org/evening-speaker-series-virtual-hematology-update2021-05-12T22:27Znever http://www.nebraskaoncology.org/annual-midwest-regional-mid-year-review-20212022-10-05T15:26Znever http://www.nebraskaoncology.org/adc-therapeutics2021-05-20T17:27Znever http://www.nebraskaoncology.org/evening-speaker-series-virtual-neuro-oncology-update2021-08-11T22:51Znever http://www.nebraskaoncology.org/evening-speaker-series-gyn-oncology-update2021-10-05T17:16Znever http://www.nebraskaoncology.org/evening-speaker-series-geriatric-oncology-update2021-11-16T18:52Znever http://www.nebraskaoncology.org/12th-annual-midwest-regional-san-antonio-breast-cancer-symposium-review2022-02-04T21:09Znever http://www.nebraskaoncology.org/evening-speaker-series-2022-virtual-lung-cancer-update2022-03-11T23:37Znever http://www.nebraskaoncology.org/annual-midwest-regional-mid-year-review-20222022-10-05T15:25Znever http://www.nebraskaoncology.org/node/52019-01-04T22:38Znever http://www.nebraskaoncology.org/evening-speaker-series-virtual-hematology-update-20222022-05-18T18:41Znever http://www.nebraskaoncology.org/2022-evening-speaker-series-hybrid-neuro-oncology-update2022-08-03T19:51Znever http://www.nebraskaoncology.org/2022-evening-speaker-series-gyn-oncology-update2022-09-16T16:59Znever http://www.nebraskaoncology.org/2022-evening-speaker-series-hybrid-survivorship-update2022-11-15T20:13Znever http://www.nebraskaoncology.org/13th-annual-winter-breast-cancer-symposium2023-02-02T16:41Znever http://www.nebraskaoncology.org/2023-evening-speaker-series-immunotherapy2023-04-21T16:59Znever http://www.nebraskaoncology.org/test-nos-new-item-one2018-05-24T20:25Znever http://www.nebraskaoncology.org/2023-evening-speaker-series-theranostics2023-05-24T21:56Znever http://www.nebraskaoncology.org/annual-midwest-regional-mid-year-review-20232023-07-12T15:05Znever http://www.nebraskaoncology.org/2023-evening-speaker-series-gynecologic-cancer2023-08-24T16:52Znever http://www.nebraskaoncology.org/2023-evening-speaker-series-survivorship2023-11-08T18:02Znever http://www.nebraskaoncology.org/some-nos-news-test-two-long-descriptive-title-about-something2018-05-24T20:25Znever http://www.nebraskaoncology.org/14th-annual-winter-breast-cancer-symposium2024-04-11T16:31Zyearly http://www.nebraskaoncology.org/2024-evening-speaker-series-gi-cancer-update2024-04-12T05:34Zyearly http://www.nebraskaoncology.org/2024-evening-speaker-series-hematology-update2024-05-24T19:13Zyearly http://www.nebraskaoncology.org/test-three-news-title2018-05-24T20:25Znever http://www.nebraskaoncology.org/annual-midwest-regional-mid-year-review-20242024-08-06T15:12Zyearly http://www.nebraskaoncology.org/2024-evening-speaker-series-lung-cancer-update2024-11-07T21:40Zyearly http://www.nebraskaoncology.org/2024-evening-speaker-series-skin-cancer-update2025-12-02T22:03Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2024/09/corporate-member-update-merck-new-indication-pembrolizumab2024-09-09T15:47Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2024/09/corporate-member-update-servier2024-09-11T18:23Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2024/10/corporate-member-update-beigene2024-10-24T17:13Zyearly http://www.nebraskaoncology.org/2025-annual-winter-breast-cancer-symposium2025-05-14T17:53Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2024/11/corporate-member-update-genentech2024-11-19T23:12Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2024/11/corporate-member-update-genentech-02024-11-19T23:16Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2024/09/corporate-member-update-astrazeneca2024-11-22T20:29Zyearly http://www.nebraskaoncology.org/2025-speaker-series-ai-oncology2025-05-05T15:48Zyearly http://www.nebraskaoncology.org/2025-speaker-series-hematologic-oncology-update2025-05-29T17:02Zyearly http://www.nebraskaoncology.org/phase-3-study-elacestrant-versus-standard-endocrine-therapy-node-positive-er-her2-early-breast2025-05-02T16:15Zyearly http://www.nebraskaoncology.org/study-abemaciclib-and-elacestrant-patients-brain-metastasis-due-er/her-2-breast-cancer-electra2025-05-02T16:17Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/05/corporate-member-update-menarini-stemline-elegant-clinical-trial-listing2025-05-02T16:25Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/01/corporate-member-update-astrazeneca2025-05-02T19:02Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/04/corporate-member-update-amgen2025-05-02T19:07Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/04/corporate-member-update-bristol-myers-squibb2025-05-02T20:05Zyearly http://www.nebraskaoncology.org/2025-annual-midwest-regional-mid-year-review2025-09-29T17:55Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/03/corporate-member-update-beigene2025-05-08T17:28Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/03/corporate-member-update-beigene-now-beone-medicines2025-05-08T17:35Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/05/corporate-member-update-jazz-pharmaceuticals2025-05-14T16:59Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/05/corporate-member-update-amgen2025-05-14T17:45Zyearly http://www.nebraskaoncology.org/2025-speaker-series-skin-cancer-update2025-08-19T00:09Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/06/corporate-member-update-jazz-pharmaceuticals2025-06-12T18:58Zyearly http://www.nebraskaoncology.org/2025-speaker-series-lung-cancer-update2025-11-18T22:27Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/07/corporate-member-update-merck2025-09-12T20:42Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/10/corporate-member-update-amgen-new-technology-add-payment/ntap-sclc2025-10-23T20:56Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/10/astrazeneca-datroway-j-code2025-11-03T20:49Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/10/fda-approves-zepzelca®-lurbinectedin-and-atezolizumab-tecentriq®2025-11-03T20:59Zyearly http://www.nebraskaoncology.org/2026-annual-winter-breast-cancer-symposium2026-02-09T23:09Zweekly http://www.nebraskaoncology.org/new-drug-therapy/2025/11/corporate-member-update-amgen2025-11-25T21:04Zyearly http://www.nebraskaoncology.org/new-drug-therapy/2025/11/corporate-member-update-merck2025-11-25T21:13Zyearly http://www.nebraskaoncology.org/about/officers2021-03-18T19:43Znever http://www.nebraskaoncology.org/about/news2019-10-10T17:43Znever http://www.nebraskaoncology.org/study-ipatasertib-gdc-00682018-07-20T14:33Znever http://www.nebraskaoncology.org/dr-peter-townley-midwest-regional-asco-review2020-12-16T21:28Znever http://www.nebraskaoncology.org/events2025-05-05T19:27Zyearly http://www.nebraskaoncology.org/clinical-trials/faqs2018-11-28T14:57Znever http://www.nebraskaoncology.org/clinical-trials/clinical-trials-patient2018-11-28T14:56Znever http://www.nebraskaoncology.org/clinical-trials/clinical-trials-physician2018-11-28T14:57Znever http://www.nebraskaoncology.org/abc2018-12-03T20:31Znever http://www.nebraskaoncology.org/abc-02018-12-03T20:31Znever http://www.nebraskaoncology.org/randomized-trial-adjuvant-doxorubicin-plus-cyclophosphamide-followed-weekly-paclitaxel-or-without2019-03-08T16:24Znever http://www.nebraskaoncology.org/randomized-trial-adjuvant-radiotherapy-or-without-cisplatin-p53-mutated-surgically-resected-squamous2019-03-08T20:58Znever